Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Rating of “Moderate Buy” by Brokerages

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has earned an average recommendation of “Moderate Buy” from the six research firms that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $5.17.

Several brokerages have weighed in on SGMO. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $2.00 price objective on shares of Sangamo Therapeutics in a report on Tuesday, March 18th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a report on Monday, April 7th. Finally, Truist Financial dropped their price objective on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, January 23rd.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of SGMO. Geode Capital Management LLC grew its position in Sangamo Therapeutics by 14.6% in the third quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company’s stock valued at $1,853,000 after acquiring an additional 272,123 shares during the last quarter. Virtu Financial LLC bought a new position in Sangamo Therapeutics in the third quarter valued at about $150,000. Shelton Wealth Management LLC bought a new position in Sangamo Therapeutics in the fourth quarter valued at about $29,000. Golden State Equity Partners grew its position in Sangamo Therapeutics by 2,592.3% in the fourth quarter. Golden State Equity Partners now owns 325,684 shares of the biopharmaceutical company’s stock valued at $332,000 after acquiring an additional 313,587 shares during the last quarter. Finally, Sageworth Trust Co bought a new position in Sangamo Therapeutics in the fourth quarter valued at about $61,000. Institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Trading Down 2.8%

Shares of NASDAQ SGMO opened at $0.70 on Monday. The firm has a market cap of $160.44 million, a P/E ratio of -0.93 and a beta of 1.46. Sangamo Therapeutics has a 1-year low of $0.30 and a 1-year high of $3.18. The business’s 50 day moving average is $0.78 and its 200-day moving average is $1.36.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). The firm had revenue of $7.55 million for the quarter, compared to the consensus estimate of $11.70 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. Analysts forecast that Sangamo Therapeutics will post -0.46 EPS for the current year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.